SEC Form 4 · accession 0001209191-17-057319
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Chodakewitz
Officer — EVP GMDA, CMO
Period of report
Oct 16, 2017
Accepted (ET)
Oct 18, 2017 · 5:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 16, 2017 | M | 1,718 | $96.87 | A | 116,142 | D | |
| Common StockF2,F3 | Oct 16, 2017 | S | 300 | $153.42 | D | 115,842 | D | |
| Common StockF2,F4 | Oct 16, 2017 | S | 818 | $154.76 | D | 115,024 | D | |
| Common StockF2 | Oct 16, 2017 | S | 300 | $155.92 | D | 114,724 | D | |
| Common StockF2 | Oct 16, 2017 | S | 300 | $157.38 | D | 114,424 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $96.87 | Oct 16, 2017 | M | 1,718 | D | — | Jul 14, 2024 | Common Stock | 1,718 | 5,157 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
- F2Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $153.42 (range $153.11 to $153.58).
- F4Open market sales reported on this line occurred at a weighted average price of $154.76 (range $154.50 to $155.15).
- F5The option vests in 16 quarterly installments from 7/15/2014.